|
Drug treatment for lysosomal storage disorders (all ages), Commissioning Policy (CP55), July 2025 (PDF, 619Kb)
|
|
Sapropterin for treating hyperphenylalaninaemia (HPA) in phenylketonuria (PKU) and tetrahydrobiopterin (BH4) disorders, Policy Position (PP223), January 2023 (PDF, 464Kb)
|
|
Volanesorsen for treating familial chylomicronaemia syndrome, Policy Position Statement, (PP217). October 2021 (PDF, 285Kb)
|